Sergio Quezada’s Programme Award to be used for Brain Tumour Therapies

Science and Innovation at Cancer Research UK shared on X:

“Sergio Quezada will use a new Programme Award to map the T-cell reactive landscape in glioblastoma multiforme to inform the development of personalised and non-personalised vaccine and cell therapies against Brain Tumours.”

Source: Science and Innovation Cancer Research UK/X

Sergio Quezada is a Professor of Cancer Immunology and Immunotherapy at the UCL Cancer Institute and Chief Scientific Officer and Co-Founder of Achilles Therapeutics Limited.

His research group at UCL investigates the precise mechanisms by which anti-CTLA-4, anti-PD-1, and other immune-modulatory antibodies target co-inhibitory and co-stimulatory pathways, including ICOS, 4-1BB, and OX-40, to develop novel anticancer therapies.